Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease LONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of
RNS Number : 8999N Renalytix PLC 26 January 2023 Renalytix plc (" Renalytix " or the " Company ") Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States Award for consortium of industry,
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA)
RNS Number : 1089M Renalytix PLC 09 January 2023 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 1075M Renalytix PLC 09 January 2023 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
RNS Number : 0077M Renalytix PLC 09 January 2023 Renalytix plc (" Renalytix " or the " Company ") Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems Significant milestone will make KidneyIntelX accessible
The 'Result of AGM' announcement released on 19/12/2022 at 12.01 under RNS No 1882K, did not include Resolutions 11 and 12. All Resolutions are now shown below and all other text remains the same.
First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patients LONDON and SALT LAKE CITY, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced
RNS Number : 1709I Renalytix PLC 01 December 2022 Renalytix plc ("Renalytix" or the "Company") Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to
LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
